Long-Term Effectiveness and Safety of Proactive Therapeutic Drug Monitoring of Infliximab in Paediatric Inflammatory Bowel Disease: A Real-World Study

Pharmaceutics, Год журнала: 2024, Номер 16(12), С. 1577 - 1577

Опубликована: Дек. 10, 2024

This study evaluated the long-term effectiveness and safety of a multidisciplinary early proactive therapeutic drug monitoring (TDM) program combined with Bayesian forecasting for infliximab (IFX) dose adjustment in real-world dataset paediatric patients inflammatory bowel disease (IBD). A descriptive, ambispective, single-centre IBD who underwent IFX serum concentration measurements between September 2015 2023. The received reactive TDM before 2019 (n = 17) thereafter 21). We analysed clinical, biological, endoscopic remission; treatment failure; hospitalisations; emergency visits; adverse reactions. doses were adjusted to maintain trough concentrations ≥ 5 µg/mL, specific targets TDM. Of 38 patients, 21 had Crohn's (CD), 16 ulcerative colitis (UC), 1 undetermined IBD. mean (standard deviation) 6.83 (5.66) µg/mL (reactive) 12.38 (9.24) (proactive) ( Proactive showed no significant differences outcomes compared However, results both groups not worse than those reported other studies. Further studies larger samples are needed optimize strategies pediatric patients.

Язык: Английский

---

Personalized Secukinumab Treatment in Patients with Plaque Psoriasis Using Model-Informed Precision Dosing

Pharmaceutics, Год журнала: 2024, Номер 16(12), С. 1576 - 1576

Опубликована: Дек. 10, 2024

Background/Objectives: Patient care and control of inflammatory disorders, such as psoriasis, can be improved by model-informed precision dosing (MIPD) techniques based on population pharmacokinetic/pharmacodynamic (PK/PD) models. Clinical dose selection decisions MIPD strategies need to take account the uncertainty associated with individual PK/PD model parameters, which is determined quantity observational data collected in clinical practice. Methods: The aim this study was propose an approach for personalized dosage regimens secukinumab (SCK) 22 Spanish patients plaque whose severity level considered moderate severe, taking into parameters a population-based model. Results: link between SCK serum concentrations Psoriasis Area Severity Index (PASI) scores explained using indirect response A maximum inhibition (Imax) drug effect applied limit progression psoriatic skin lesions within turnover PD mechanism, explains changes PASI during treatment. first-order remission rate constant (kout = 0.11 day−1) estimated. Conclusions: According strategy, 50% would require optimized regimen 14% intensified comparison current This research has shown its usefulness tool choosing individualized long-lasting psoriasis improve probability achieving satisfactory levels.

Язык: Английский

---

Intensified infliximab induction therapy for steroid-refractory acute severe ulcerative colitis

˜The œLancet. Gastroenterology & hepatology, Год журнала: 2024, Номер 10(1), С. 18 - 19

Опубликована: Дек. 11, 2024

Язык: Английский

---

Therapeutic drug monitoring—Does it really matter?

British Journal of Clinical Pharmacology, Год журнала: 2024, Номер unknown

Опубликована: Дек. 30, 2024

Язык: Английский

---